Adjuvant Therapy for Resected Biliary Tract Cancer

ASCO Clinical Practice Guideline

Rachna T. Shroff, Erin B. Kennedy, Melinda Bachini, Tanios Bekaii-Saab, Christopher Crane, Julien Edeline, Anthony El-Khoueiry, Mary Feng, Matthew H.G. Katz, John Primrose, Heloisa P. Soares, Juan Valle, Shishir K. Maithel

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

PURPOSE: To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with resected biliary tract cancer. METHODS: ASCO convened an Expert Panel to conduct a systematic review of the literature on adjuvant therapy for resected biliary tract cancer and provide recommended care options for this patient population. RESULTS: Three phase III randomized controlled trials, one phase II trial, and 16 retrospective studies met the inclusion criteria. RECOMMENDATIONS: Based on evidence from a phase III randomized controlled trial, patients with resected biliary tract cancer should be offered adjuvant capecitabine chemotherapy for a duration of 6 months. The dosing used in this trial is described in the qualifying statements, while it should be noted that the dose of capecitabine may also be determined by institutional and regional practices. Patients with extrahepatic cholangiocarcinoma or gallbladder cancer and a microscopically positive surgical resection margin (R1 resection) may be offered chemoradiation therapy. A shared decision-making approach is recommended, considering the risk of harm and potential for benefit associated with radiation therapy for patients with extrahepatic cholangiocarcinoma or gallbladder cancer. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .

Original languageEnglish (US)
Pages (from-to)1015-1027
Number of pages13
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology
Volume37
Issue number12
DOIs
StatePublished - Apr 20 2019

Fingerprint

Biliary Tract Neoplasms
Practice Guidelines
Gallbladder Neoplasms
Cholangiocarcinoma
Randomized Controlled Trials
Institutional Practice
Gastrointestinal Neoplasms
Evidence-Based Practice
Therapeutics
Adjuvant Chemotherapy
Decision Making
Patient Care
Radiotherapy
Retrospective Studies
Guidelines
Population
Margins of Excision
Capecitabine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Adjuvant Therapy for Resected Biliary Tract Cancer : ASCO Clinical Practice Guideline. / Shroff, Rachna T.; Kennedy, Erin B.; Bachini, Melinda; Bekaii-Saab, Tanios; Crane, Christopher; Edeline, Julien; El-Khoueiry, Anthony; Feng, Mary; Katz, Matthew H.G.; Primrose, John; Soares, Heloisa P.; Valle, Juan; Maithel, Shishir K.

In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 37, No. 12, 20.04.2019, p. 1015-1027.

Research output: Contribution to journalArticle

Shroff, RT, Kennedy, EB, Bachini, M, Bekaii-Saab, T, Crane, C, Edeline, J, El-Khoueiry, A, Feng, M, Katz, MHG, Primrose, J, Soares, HP, Valle, J & Maithel, SK 2019, 'Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 37, no. 12, pp. 1015-1027. https://doi.org/10.1200/JCO.18.02178
Shroff, Rachna T. ; Kennedy, Erin B. ; Bachini, Melinda ; Bekaii-Saab, Tanios ; Crane, Christopher ; Edeline, Julien ; El-Khoueiry, Anthony ; Feng, Mary ; Katz, Matthew H.G. ; Primrose, John ; Soares, Heloisa P. ; Valle, Juan ; Maithel, Shishir K. / Adjuvant Therapy for Resected Biliary Tract Cancer : ASCO Clinical Practice Guideline. In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 ; Vol. 37, No. 12. pp. 1015-1027.
@article{e37da9c592004daea4baaa137af80181,
title = "Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline",
abstract = "PURPOSE: To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with resected biliary tract cancer. METHODS: ASCO convened an Expert Panel to conduct a systematic review of the literature on adjuvant therapy for resected biliary tract cancer and provide recommended care options for this patient population. RESULTS: Three phase III randomized controlled trials, one phase II trial, and 16 retrospective studies met the inclusion criteria. RECOMMENDATIONS: Based on evidence from a phase III randomized controlled trial, patients with resected biliary tract cancer should be offered adjuvant capecitabine chemotherapy for a duration of 6 months. The dosing used in this trial is described in the qualifying statements, while it should be noted that the dose of capecitabine may also be determined by institutional and regional practices. Patients with extrahepatic cholangiocarcinoma or gallbladder cancer and a microscopically positive surgical resection margin (R1 resection) may be offered chemoradiation therapy. A shared decision-making approach is recommended, considering the risk of harm and potential for benefit associated with radiation therapy for patients with extrahepatic cholangiocarcinoma or gallbladder cancer. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .",
author = "Shroff, {Rachna T.} and Kennedy, {Erin B.} and Melinda Bachini and Tanios Bekaii-Saab and Christopher Crane and Julien Edeline and Anthony El-Khoueiry and Mary Feng and Katz, {Matthew H.G.} and John Primrose and Soares, {Heloisa P.} and Juan Valle and Maithel, {Shishir K.}",
year = "2019",
month = "4",
day = "20",
doi = "10.1200/JCO.18.02178",
language = "English (US)",
volume = "37",
pages = "1015--1027",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "12",

}

TY - JOUR

T1 - Adjuvant Therapy for Resected Biliary Tract Cancer

T2 - ASCO Clinical Practice Guideline

AU - Shroff, Rachna T.

AU - Kennedy, Erin B.

AU - Bachini, Melinda

AU - Bekaii-Saab, Tanios

AU - Crane, Christopher

AU - Edeline, Julien

AU - El-Khoueiry, Anthony

AU - Feng, Mary

AU - Katz, Matthew H.G.

AU - Primrose, John

AU - Soares, Heloisa P.

AU - Valle, Juan

AU - Maithel, Shishir K.

PY - 2019/4/20

Y1 - 2019/4/20

N2 - PURPOSE: To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with resected biliary tract cancer. METHODS: ASCO convened an Expert Panel to conduct a systematic review of the literature on adjuvant therapy for resected biliary tract cancer and provide recommended care options for this patient population. RESULTS: Three phase III randomized controlled trials, one phase II trial, and 16 retrospective studies met the inclusion criteria. RECOMMENDATIONS: Based on evidence from a phase III randomized controlled trial, patients with resected biliary tract cancer should be offered adjuvant capecitabine chemotherapy for a duration of 6 months. The dosing used in this trial is described in the qualifying statements, while it should be noted that the dose of capecitabine may also be determined by institutional and regional practices. Patients with extrahepatic cholangiocarcinoma or gallbladder cancer and a microscopically positive surgical resection margin (R1 resection) may be offered chemoradiation therapy. A shared decision-making approach is recommended, considering the risk of harm and potential for benefit associated with radiation therapy for patients with extrahepatic cholangiocarcinoma or gallbladder cancer. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .

AB - PURPOSE: To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with resected biliary tract cancer. METHODS: ASCO convened an Expert Panel to conduct a systematic review of the literature on adjuvant therapy for resected biliary tract cancer and provide recommended care options for this patient population. RESULTS: Three phase III randomized controlled trials, one phase II trial, and 16 retrospective studies met the inclusion criteria. RECOMMENDATIONS: Based on evidence from a phase III randomized controlled trial, patients with resected biliary tract cancer should be offered adjuvant capecitabine chemotherapy for a duration of 6 months. The dosing used in this trial is described in the qualifying statements, while it should be noted that the dose of capecitabine may also be determined by institutional and regional practices. Patients with extrahepatic cholangiocarcinoma or gallbladder cancer and a microscopically positive surgical resection margin (R1 resection) may be offered chemoradiation therapy. A shared decision-making approach is recommended, considering the risk of harm and potential for benefit associated with radiation therapy for patients with extrahepatic cholangiocarcinoma or gallbladder cancer. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .

UR - http://www.scopus.com/inward/record.url?scp=85065042220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065042220&partnerID=8YFLogxK

U2 - 10.1200/JCO.18.02178

DO - 10.1200/JCO.18.02178

M3 - Article

VL - 37

SP - 1015

EP - 1027

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 12

ER -